Swiss drug company Novartis has hinted that it could charge as much as $4 to $5 million for a new gene therapy, according to Reuters.
Rare disease: The gene replacement treatment, not yet approved, is for type 1 spinal muscular atrophy, a fatal inherited disease that strikes 1 in 20,000 toddlers. A single dose of the therapy appears to prevent the disease if given shortly after birth. In other words, it looks like a true cure.
Strike it rich: The gene therapy technology was spun out by Nationwide Children’s Hospital into a startup, AveXis, which tested it in a dozen or so children. Earlier this year, Novartis acquired AveXis for almost $9 billion. The deal made a few people very wealthy. It also pretty much guaranteed an eye-watering price tag.
Pay up: Novartis hasn’t announced a final price, but according to Reuters, Dave Lennon, president of AveXis, said during a conference call that “four million dollars is a significant amount of money, but we believe this is a cost-effective point.” The previous record price for a drug was about $1 million for Glybera, also a gene therapy.
Why so much? Rare diseases are, well, really rare. And drug companies think in terms of blockbusters. The only way to turn a rare-disease treatment that’s given just once into a profit-maker is to charge ultra-high prices.
Life or death: Expect Novartis to face tough questions going forward. One critic on Twitter noted that ransoms paid to criminal gangs to release hostages are often only about $2 million.
The feud between a weed influencer and scientist over puking stoners
A scientist went looking for genes that cause cannabinoid hyperemesis syndrome. But a public spat with a cannabis influencer who suffers from the disease may have derailed his research.
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
Edits to a cholesterol gene could stop the biggest killer on earth
In a first, a patient in New Zealand has undergone gene-editing to lower their cholesterol. It could be the beginning of new era in disease prevention.
Monkeypox is in Bay Area wastewater
It showed up in Stanford’s Sewer Coronavirus Alert Network, which is the only group publishing data on monkeypox in US wastewater.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.